Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Hope

Showing results (261-270 of 365) with videos related to

Pageof 37
Sort By:
Antimicrobial Agents and Chemotherapy|March 6, 2019
Generating Robust and Informative Nonclinical <i>In Vitro</i> and <i>In Vivo</i> Bacterial Infection Model Efficacy Data To Support Translation to HumansJürgen B Bulitta, William W Hope, Ann E Eakin, et al.
Antimicrobial Agents and Chemotherapy|November 8, 2006
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasisWilliam W Hope, George L Drusano, Caroline B Moore, et al.
Antimicrobial Agents and Chemotherapy|September 7, 2006
Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effectWilliam W Hope, Peter A Warn, Andrew Sharp, et al.
Antimicrobial Agents and Chemotherapy|August 3, 2011
Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hostsSusan J Howard, Joanne Livermore, Andrew Sharp, et al.
The American Surgeon|February 12, 2018
Incisional Hernia in the United States: Trends in Hospital Encounters and Corresponding Healthcare ChargesValeriy Shubinets, Justin P Fox, Michael A Lanni, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2007
Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosingWilliam W Hope, Peter A Warn, Andrew Sharp, et al.
The Journal of Infectious Diseases|March 2, 2011
Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapySusan J Howard, Jodi M Lestner, Andrew Sharp, et al.
Antimicrobial Agents and Chemotherapy|November 2, 2012
Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infectionJ L Livermore, T W Felton, J Abbott, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 13, 2018
Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coliV Merino-Bohórquez, F Docobo-Pérez, J Sojo, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2021
Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of CoccidioidomycosisLaura L Kovanda, Gabriele Sass, Marife Martinez, et al.
Pageof 37

Showing results (261-270 of 365) with videos related to

Sort By:
Pageof 37
Antimicrobial Agents and Chemotherapy|March 6, 2019
Generating Robust and Informative Nonclinical <i>In Vitro</i> and <i>In Vivo</i> Bacterial Infection Model Efficacy Data To Support Translation to HumansJürgen B Bulitta, William W Hope, Ann E Eakin, et al.
Antimicrobial Agents and Chemotherapy|November 8, 2006
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasisWilliam W Hope, George L Drusano, Caroline B Moore, et al.
Antimicrobial Agents and Chemotherapy|September 7, 2006
Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effectWilliam W Hope, Peter A Warn, Andrew Sharp, et al.
Antimicrobial Agents and Chemotherapy|August 3, 2011
Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hostsSusan J Howard, Joanne Livermore, Andrew Sharp, et al.
The American Surgeon|February 12, 2018
Incisional Hernia in the United States: Trends in Hospital Encounters and Corresponding Healthcare ChargesValeriy Shubinets, Justin P Fox, Michael A Lanni, et al.
Antimicrobial Agents and Chemotherapy|August 8, 2007
Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosingWilliam W Hope, Peter A Warn, Andrew Sharp, et al.
The Journal of Infectious Diseases|March 2, 2011
Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapySusan J Howard, Jodi M Lestner, Andrew Sharp, et al.
Antimicrobial Agents and Chemotherapy|November 2, 2012
Pharmacokinetics and pharmacodynamics of anidulafungin for experimental Candida endophthalmitis: insights into the utility of echinocandins for treatment of a potentially sight-threatening infectionJ L Livermore, T W Felton, J Abbott, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|April 13, 2018
Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coliV Merino-Bohórquez, F Docobo-Pérez, J Sojo, et al.
Antimicrobial Agents and Chemotherapy|March 30, 2021
Efficacy and Associated Drug Exposures of Isavuconazole and Fluconazole in an Experimental Model of CoccidioidomycosisLaura L Kovanda, Gabriele Sass, Marife Martinez, et al.
Pageof 37